Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb…
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…
The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second…
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
Epidemiology Data Slicer – Rheumatoid Arthritis
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs (cDMARDs), such as methotrexate. For patients who fail cDMARD treatment, or exhibit an inadequate…
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF targeted therapy (e.g., Bristol Myers Squibb…
The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second…
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
MARKET OUTLOOK Rheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone…